ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
The Growing Influence of the Institute of Clinical and… 11/21/2019